Primary tumor (n = 70) | Metastases (n = 49) | Clinical practicea (n = 102) | |
---|---|---|---|
No. (%) | No. (%) | No. (%) | |
ER status | |||
< 1% | 3 (4.3) | 0 | 2 (2.0) |
≥ 1% | 65 (92.9) | 49 (100) | 100 (98.0) |
Unknown | 2 (2.8) | 0 | 0 |
PgR status | |||
< 1% | 10 (14.3) | 12 (24.5) | 22 (21.6) |
≥ 1% | 58 (82.9) | 37 (75.5) | 80 (78.4) |
Unknown | 2 (2.8) | 0 | 0 |
Ki67 status | |||
< 20% | 39 (55.7) | 30 (61.2) | 63 (61.8) |
≥ 20% | 27 (38.6) | 17 (34.7) | 38 (37.2) |
Unknown | 4 (5.7) | 2 (4.1) | 1 (1) |
HER2 status | |||
Negative | 57 (81.4) | 41 (83.7) | 88 (86.3) |
Positive | 10 (14.3) | 7 (14.3) | 14 (13.7) |
Unknown | 3 (4.3) | 1 (2) | 0 |
AR status | |||
< 1% | 5 (7.1) | 12 (24.5) | 17 (16.7) |
≥ 1% | 65 (92.9) | 37 (75.5) | 85 (83.3) |
< 10% | 7 (10.0) | 19 (38.8) | 26 (25.5) |
≥ 10% | 63 (90.0) | 30 (61.2) | 76 (74.5) |